Compare NTLA & STEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | STEL |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2016 | 2017 |
| Metric | NTLA | STEL |
|---|---|---|
| Price | $13.63 | $37.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 2 |
| Target Price | $20.02 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 5.6M | 260.9K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $67,671,000.00 | $6,282,000.00 |
| Revenue This Year | N/A | $10.14 |
| Revenue Next Year | $62.75 | $4.65 |
| P/E Ratio | ★ N/A | $70.92 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $26.30 |
| 52 Week High | $28.24 | $40.21 |
| Indicator | NTLA | STEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 57.28 |
| Support Level | $11.55 | $36.95 |
| Resistance Level | $14.02 | $38.02 |
| Average True Range (ATR) | 0.94 | 0.49 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 50.27 | 99.22 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc. and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.